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Background: The objective of this study was to systematically evaluate the contribution of the insulin-like growth
factor 2 mRNA-binding protein 2 (IGF2BP2) to type 2 diabetes mellitus (T2DM) and its interaction with obesity to
T2DM susceptibility.
Methods: To clarify whether IGF2BP2 is an independent risk factor for T2DM in Chinese population, we conducted
a study with a total of 2,301 Chinese Han subjects, including 1,166 T2DM patients and 1,135 controls, for the genotype
of a most common and widely studied polymorphism—rs4402960 of IGF2BP2. Genotyping was performed by iPLEX
technology. Gene and environment interaction analysis was performed by using multiple logistic regression models.
Results: The repeatedly confirmed association between IGF2BP2 (rs4402960) and T2DM had not been replicated in this
cohort (P = 0.182). Interestingly, we found that obese subjects (body mass index (BMI)≥ 28.0 kg/m2) bearing the minor
A allele had an increased risk to develop T2DM (P = 0.008 for allele analysis and P < 0.001 for genotype analysis).
Conclusions: The present study provided data suggesting that the wild C allele of IGF2BP2 (rs4402960) had a
protective effect against T2DM in obese subjects of Chinese Han population.
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Type 2 diabetes mellitus (T2DM) is a complex metabolic
disorder characterized by hyperglycemia as a result of
pancreatic beta cell dysfunction and insulin resistance.
Multiple environmental factors and genetic determinants
are considered to be involved in the pathogenesis of the
disease. Genome-wide association studies (GWAS) have
emerged as a powerful approach for identifying novel
genetic variants contributing to the risk of T2DM and
further facilitate the elucidation of the genetic etiology
of diabetes. Among the variants relating to glucose
metabolism revealed by GWAS, insulin-like growth
factor 2 mRNA-binding protein 2 (IGF2BP2) was the
most extensively studied and supposed to be a T2DM
susceptibility gene [1-3].* Correspondence: wenjie065@126.com
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unless otherwise stated.IGF2BP2 is encoded by the IGF2BP2 gene which is
located on chromosome 3q27. Its strong association
with β cell function is established by regulating IGF2
post-translation [4]. Several variants of the IGF2BP2
gene were investigated for relationship with T2DM, of
which rs4402960 was the most extensively studied.
However, due to the ethnic difference in risk allele fre-
quency, the contribution of this common variant to
T2DM appears to be race dependent which makes it a
highly controversial candidate for T2DM [1-3,5]. To
get a thorough understanding of the effect of IGF2BP2
on the susceptibility of T2DM, we therefore genotyped
for IGF2BP2 rs4402960 in a total of 2,301 Chinese Han
individuals in our present study.
Given that environment/lifestyle changes can modify
the risk of T2DM, likely contributing factors such as
gender, body mass index (BMI), and smoking behavior
of subjects to T2DM would also be interesting to inves-
tigate [6]. Obesity (BMI ≥ 28.0 kg/m2) is especially widely
recognized as an independent risk factor for T2DM in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to conduct a particular analysis for obesity in this cohort.
Previous studies provided evidence for gene-obesity
interaction in human complex disease [8,9]. Studies
also supported the assumption that IGF2 is strongly
associated with obesity [10]. It is evident that obesity is
associated with T2DM, and IGF2 levels in T2DM pa-
tients are associated with T2DM. We hypothesize that
obesity may modify the association between IGF2BP2
and T2DM—also called the interaction of IGF2BP2 and
obesity with T2DM. Since some variants are known to
affect the risk of T2DM through obesity [11,12], this work
aimed to evaluate the interaction effect of IGF2BP2 and
obesity on T2DM susceptibility.Methods
Study population
Individuals enrolled in the cohort, including 1,166 T2DM
patients and 1,135 controls, were of Southern Han
Chinese ancestry residing in the Shanghai metropolitan
area. T2DM patients registered in the analysis were
recruited from the Endocrinology and Metabolism out-
patient clinics at Fudan University Huashan Hospital in
Shanghai. All subjects in the cohort were informed and
consented to take part in the study. The protocol was
approved by the Ethics Committee of Huashan Hospital
affiliated to Fudan University.Table 1 The clinical characteristics of the subjects
Variables Diabetics Controls
N 1,166 1,135
Age (years) 65.46 ± 10.56 59.09 ± 7.85
Sex (male/female) 456/710 352/783
Height (cm) 160.20 ± 8.64 161.09 ± 7.65
Weight (kg) 64.85 ± 10.71 62.78 ± 10.15
SBP (mmHg) 139.52 ± 19.92 126.44 ± 16.92
DBP (mmHg) 82.88 ± 10.98 80.52 ± 10.13
BUN (mg/dl) 6.08 ± 1.63 5.62 ± 1.37
UA (mg/dl) 0.30 ± 0.08 0.31 ± 0.08
FPG (mmol/l) 8.39 ± 3.03 5.22 ± 0.38
PPG (mmol/l) 15.05 ± 5.34 6.03 ± 1.04
TC (ml/dl) 5.43 ± 1.11 5.35 ± 1.00
TG (ml/dl) 2.00 ± 1.46 1.47 ± 1.06
HDL (mmol/l) 1.29 ± 0.34 1.43 ± 0.36
LDL (mmol/l) 3.10 ± 0.86 3.10 ± 0.79
ALT (IU/l) 28.44 ± 16.08 24.04 ± 13.69
rs4402960 (A/C) 27.03%/72.97% 25.27%/74.73%
SBP systolic blood pressure, DBP diastolic blood pressure, BUN blood urea nitrogen,
UA uric acid, FPG fasting plasma glucose, PPG postprandial plasma glucose, TC total
cholesterol, TG triglyceride, HDL high-density lipoprotein cholesterol, LDL
low-density lipoprotein cholesterol, ALT alanine transaminase.Measurements
The subjects were interviewed for the documentation of
medical histories, medications, regular physical examina-
tions, and laboratory assessment of T2DM risk factors.
BMI was calculated as the weight in kilograms divided
by the square of height in meters. Systolic and diastolic
blood pressure (BP) values were the means of two
physician-obtained measurements on the left arm of a
seated participant.
Peripheral venous blood samples were collected in
tubes in the fasting state and 2 h after diet in all subjects.
The blood was centrifuged at 3,000 rpm for 10 min for
plasma separation and immediately used to measure bio-
markers. Fasting plasma glucose (FPG) and postprandial
plasma glucose (PPG) were quantified by the glucose
oxidase-peroxidase procedure. Serum total cholesterol
(TC), triglyceride (TG), high-density lipoprotein (HDL)
cholesterol, urea nitrogen (UN), uric acid (UA), and ala-
nine transaminase (ALT) levels were measured by an
enzymatic method with a chemical analyzer (Hitachi
7600-020, Tokyo, Japan). Low-density lipoprotein (LDL)
cholesterol levels were calculated using the Friedewald
formula. The day-to-day and inter-assay coefficients of
variation at the central laboratory in our hospital for all
analyses were between 1% and 3%.Definition
Hypertension (HT) was defined as blood pressure ≥140/
90 mmHg or a history of hypertension medication. BMI
was classified based on the Chinese criteria: obese [13]
(BMI ≥ 28.0 kg/m2). The definition of high serum TG
was TG ≥ 150 mg/dl, and that of high serum TC was
TC ≥ 200 ml/dl. Diabetes was defined according to the
1999 WHO criteria [14]: fasting plasma glucose ≥7.0 mmol/l
and/or 2-h plasma glucose ≥11.1 mmol/l in the oral
glucose tolerance test (OGTT). All diabetic patients
were unrelated and diagnosed after the age of 27 years.
Known subtypes of diabetes, such as type 1 diabetes,
gestational diabetes, rare forms of T2DM, and secondary
diabetes (pancreatitis, hemochromatosis), were excluded
based on antibody measurements and inheritance. The
nondiabetic unrelated individuals were identified as the
control population based on the following criteria: (1) no
family history of diabetes, (2) ≥45 years of age, and (3)
normal glucose tolerance verified by OGTT. The clinical
characteristics of the participants are summarized in
Table 1.
SNP genotyping
Peripheral venous blood samples were collected from all
study subjects, and the genomic DNA was extracted
from peripheral blood leukocytes by the conventional
proteinase K-phenol-chloroform extraction method. A
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for IGF2BP2 rs4402960 by using iPLEX (Sequenom,
San Diego, CA, USA); the single nucleotide polymorphism
(SNP) involved was detected by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry.
The genotype distribution was in Hardy-Weinberg equi-
librium (P > 0.05), and there was a 99.9% genotype con-
cordance rate when duplicated samples were compared
across plates.Statistical analysis
Continuous variables were detected when the variables
followed normal distribution using the Kolmogorov-
Smirnov test. Variables that were not normally distributed
were log-transformed to approximate normal distribution
for analysis. Results are described as mean ± SD or median
unless stated otherwise. Differences in variables between
T2DM and control were determined by unpaired t test.
Between-group differences in properties were accessed by
χ2 analysis. Univariate logistic regression was performed
to determine variables associated with T2DM and to esti-
mate confounding factors possibly disturbing the relation
of BMI and/or IGF2BP2 to T2DM. Multivariable logistic
regression (MLR) was carried out to control potential
confounders for determining the independent contri-
bution of variables to T2DM. For interaction analysis,
MLR was conducted to include two main variables and
their interaction item to determine the interaction effect.
In order to better investigate the interaction between
BMI and IGF2BP2 on T2DM, we performed two ana-
lyses according to the following variables: the allele
and genotype of IGF2BP2. Odds ratios (OR) with 95%
confidence intervals (CI) were calculated for the rela-
tive risk of BMI and/or IGF2BP2 with T2DM. Results
were analyzed using the Statistical Package for the
Social Sciences for Windows version 16.0 (SPSS, Chicago,
IL, USA). Tests were two-sided, and a P value of <0.05
was considered significant.Table 2 Univariate logistic regression analysis for diabetes
Variables β S.E. P value OR 95% CI
Age 0.07 0.003 <0.001 1.07 1.07–1.08
Sex −0.35 0.06 <0.001 0.70 0.62–0.80
BMI 0.60 0.08 <0.001 1.81 1.54–2.14
HT 1.21 0.09 <0.001 3.36 2.83–3.99
TC 0.07 0.03 0.01 1.07 1.02–1.14
TG 0.46 0.03 <0.001 1.59 1.48–1.70
UA 0.03 0.09 0.74 1.03 0.87–1.22
IGF2BP2 0.09 0.07 0.18 1.09 0.96–1.25
IGF2BP2 with SNP rs4402960, HT hypertension, S.E. standard error.Results
Clinical characteristics of the subjects
The baseline clinical characteristics of the 2,301 subjects
are listed in Table 1. There are 456 males and 710
females (mean age, 65.46 ± 10.56 years) in the cases and
352 males and 783 females (mean age, 59.09 ± 7.85 years)
in the controls. Diabetic patients had more weight than
controls. Systolic blood pressure (SBP), diastolic blood
pressure (DBP), FPG, PPG, TC, and TG levels were higher
in the cases than in the controls, while the HDL level was
lower in the cases. Serum UA, UN, ALT, and LDL levels
were similar between the two groups. The minor allele (A)
frequency of rs4402960 was 25.27% and 27.03% in the
cases and controls, respectively.Univariate and multiple logistic regression analyses
for diabetes
To estimate the association of various clinical factors
and T2DM, univariate logistic regression models were
developed to include age, sex, BMI, hypertension, lipid
profiles, UA, and SNP (rs4402960) (Table 2). The univari-
ate logistic analyses indicated that age, sex, BMI, hyperten-
sion, and TC were significantly associated with T2DM
(P < 0.05 for all), except for UA and SNP (rs4402960)
(P = 0.744 and 0.182, respectively). The proportion of
T2DM was 48.17% and 62.75% in the low-BMI group
and high-BMI group, respectively. In subjects with high
BMI (more than 28.0 kg/m2), the OR for T2DM was 1.813
(95% CI 1.538–2.136, P < 0.001). MLR demonstrated that
BMI remained significantly different between the cases
and controls after adjustment for potential confounders
(P < 0.05, data not shown).
BMI by IGF2BP2 interaction analysis for diabetes
In the model of rs440296 with the allele variable, MLR
models were developed to include two main effect vari-
ables: BMI and rs4402960. The interaction item among
them was detected in the MLR model after adjustment
for relevant potential confounders (P = 0.023, Table 3
and Figure 1), and the interaction effect was also esti-
mated (ORInt = 1.603, 95% CI 1.068–2.405). In another
model of rs440296 with the genotype variable, the
interaction term of BMI and rs4402960 was detected
by the same method (P = 0.001, Table 4 and Figure 2),
as well as the interaction effect (ORInt = 1.661, 95% CI
1.235–2.233). In these two models, MLR models signi-
fied that BMI was a significant and independent risk
factor for T2DM, while rs4402960 alone was not
significantly associated with T2DM. The interaction
terms of BMI and SNP rs4402960 which were detected
in the two models only confirmed a significant associ-
ation between this SNP and T2DM in the high-BMI
group (P = 0.008 for allele analysis and P < 0.001 for geno-
type analysis, data not shown).
Table 3 The interaction effect analysis of BMI and allele
of IGF2BP2 (rs4402690) for diabetes
Variables β S.E. P value OR 95.0% CI
BMI 0.53 0.10 <0.0001 1.70 1.40–2.05
rs4402690 (A/C) 0.04 0.07 0.59 1.04 0.90–1.20
BMI by rs4402690 0.47 0.21 0.02 1.60 1.07–2.41
Model adjusted for age, sex, HT, TC, and TG. S.E. standard error.
Table 4 The interaction effect analysis of BMI and genotype
of IGF2BP2 (rs4402690) for diabetes
Variables β S.E. P value OR 95.0% CI
BMI 0.41 0.11 <0.001 1.50 1.21–1.86
rs4402960 (AA/CA/CC) 0.04 0.05 0.46 1.04 0.94–1.15
BMI by rs4402960 0.51 0.15 0.001 1.66 1.24–2.23
Model adjusted for age, sex, HT, TC, and TG. S.E. standard error.
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We conducted a study to evaluate the interaction effect
of IGF2BP2 and obesity on T2DM in a large case-control
sample of Chinese population. To our knowledge, this is
the first investigation of the evaluation of interaction effect
on T2DM based on variables of obesity and IGF2BP2.
Genotyping was performed for IGF2BP2 (rs4402960)
in a T2DM case-control cohort comprising of 2,301
Chinese Han individuals. However, the documented
association of IGF2BP2 (rs4402960) with T2DM in vari-
ous ethnic populations [15-18] had not been replicated. In
line with our finding, subsequent large-scale population
studies also reported a lack of association in Caucasians
[19-21]. Such conflicting results of various association
studies may be attributed to the diverse ethnic/regional
backgrounds, as well as the limited number of participants
which had insufficient statistical power to detect a
slight effect of the common polymorphism IGF2BP2
(rs4402960) on T2DM susceptibility. Therefore, a larger
sample size is necessary to detect the association between
this IGF2BP2 genetic variant and T2DM.
IGF2BP2 in pancreatic and adipose tissues can down-
regulate the expression of IGF2, a growth factor that
plays a pivotal role in controlling adipogenesis [22] andFigure 1 The interaction analysis of BMI and SNP (rs4402960
with the C/A allele) for diabetes.pancreatic development [23]. Therefore, IGF2BP2 may
contribute to T2DM through impaired β cell function or
alterations in adipose tissue as well. Consistent with the
hypothesis, a study observed a more than twofold increase
in IGF2BP2 expression level in the adipose tissue of
diabetic patients compared to controls [20]. Similarly,
an altered expression of IGF2BP2 in adipocytes of
T2DM subjects compared with healthy people was also
detected [24]. Unfortunately, the current study did not
find a significant association between IGF2PB2 (rs4402960)
and T2DM, as a consequence of the insufficient statistical
power in the present sample size or the different impacts
of various IGF2BP2 genetic variants. Further studies are
required to elucidate the association of other IGF2BP2
variants with the risk of T2DM.
Considering that lifestyle changes can modify the risk
of T2DM, the likely effect of metabolic quantitative traits
on T2DM susceptibility needs to be addressed, as well as
their interaction with various gene variants. Here, MLR
models were developed to demonstrate that obesity (BMI
≥28.0 kg/m2) remained an independently risk factor for
T2DM after potential confounder adjustment (P < 0.05,
data not shown). Although it had been known for decades
that both T2DM and obesity have a genetic basis [25], theFigure 2 The interaction analysis of BMI and SNP (rs4402960
with the CC/CA/AA genotype) for diabetes.
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is still unclear. Since some genetic variants are known to
affect the risk of T2DM through obesity, a hypothesis
comes up that IGF2BP2 may have a relationship with
obesity. However, no significant difference in IGF2BP2
expression in obese patients carrying different rs4402960
genotypes has been found [20].
Our study is the first analysis of the interaction of
obesity and IGF2BP2 variant on T2DM susceptibility. It
is noteworthy that the risk imparted by the minor A
allele was higher than that by the C allele in obese subjects
(P = 0.008 for allele analysis and P < 0.001 for genotype
analysis), thus prompting the speculation of a possible
interaction between IGF2BP2 (rs4402960) and obesity in
determining overall T2DM risk. However, the underlying
mechanism has been still unknown. The associations
between variants of IGF2BP2 and abdominal/visceral
total fat were evidenced in Canadian Caucasians [26]
and Mexican Americans [12], suggesting a possible role
of IGF2BP2 in insulin resistance. This finding implies
that IGF2BP2 (rs4402960) may disturb T2DM susceptibil-
ity through its contribution to insulin resistance, which is
experienced mainly by obese individuals.
Several limitations of the study deserve comment.
Firstly, the subjects who participated in the study were
recruited from Shanghai, so they may not have been
representative of China as a whole. Secondly, it is import-
ant to mention that our study was performed on Chinese
individuals, and our findings may not be relevant to
people of other ethnicities.Conclusions
The present study did not replicate the association of
IGF2BP2 (rs4402960) and T2DM. Interestingly, it pro-
vided data suggesting that the wild C allele of IGF2BP2
(rs4402960) had a protective effect against T2DM in
obese subjects of Chinese Han population. Further
studies and a larger sample size are required to eluci-
date the relevant mechanisms, as well as the likely
contribution of other IGF2BP2 variants to the risk of
T2DM.
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